Telaglenastat (CB-839) is a first-in-class, selective, reversible, and orally active Glutaminase-1 (GLS1) inhibitor. Telaglenastat selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC50s are 23 nM and 28 nM for endogenous glutaminase in mouse kidneys and brains, respectively. Telaglenastat induces autophagy...